Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 May;60(5):523-531.
doi: 10.1165/rcmb.2018-0384OC.

Genome-Wide Association Analysis of Single-Breath DlCO

Phuwanat Sakornsakolpat  1   2 , Meredith McCormack  3   4 , Per Bakke  5 , Amund Gulsvik  5 , Barry J Make  6 , James D Crapo  6 , Michael H Cho  1   7 , Edwin K Silverman  1   7
Affiliations
Randomized Controlled Trial

Genome-Wide Association Analysis of Single-Breath DlCO

Phuwanat Sakornsakolpat et al. Am J Respir Cell Mol Biol. 2019 May.

Abstract

DlCO is a widely used pulmonary function test in clinical practice and a particularly useful measure for assessing patients with chronic obstructive pulmonary disease (COPD). We hypothesized that elucidating genetic determinants of DlCO could lead to better understanding of the genetic architecture of COPD. We estimated the heritability of DlCO using common genetic variants and performed genome-wide association analyses in four cohorts enriched for subjects with COPD (COPDGene [Genetic Epidemiology of COPD], NETT [National Emphysema Treatment Trial], GenKOLS [Genetics of Chronic Obstructive Lung Disease study], and TESRA [Treatment of Emphysema With a Gamma-Selective Retinoid Agonist study]) using a combined European ancestry white dataset and a COPDGene African American dataset. We assessed our genome-wide significant and suggestive associations for DlCO in previously reported genome-wide association studies of COPD and related traits. We also characterized associations of known COPD-associated variants and DlCO. We estimated the SNP-based heritability of DlCO in the European ancestry white population to be 22% (P = 0.0004). We identified three genome-wide significant associations with DlCO: variants near TGFB2, CHRNA3, and PDE11A loci (P < 5 × 10-8). In addition, 12 loci were suggestively associated with DlCO in European ancestry white (P < 1 × 10-5 in the combined analysis and P < 0.05 in both COPDGene and GenKOLS), including variants near NEGR1, CADM2, PCDH7, RETREG1, DACT2, NRG1, ANKRD18A, KRT86, NTN4, ARHGAP28, INSR, and PCBP3. Some DlCO-associated variants were also associated with COPD, emphysema, and/or spirometric values. Among 25 previously reported COPD loci, TGFB2, CHRNA3/CHRNA5, FAM13A, DSP, and CYP2A6 were associated with DlCO (P < 0.001). We identified several genetic loci that were significantly associated with DlCO and characterized effects of known COPD-associated loci on DlCO. These results could lead to better understanding of the heterogeneous nature of COPD.

Trial registration: ClinicalTrials.gov NCT00608764 NCT00292552.

Keywords: D; chronic obstructive pulmonary disease; genome-wide association study.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Regional association plot for rs3009947 (TGFB2 locus at 1q41) using a combined European ancestry white dataset.
Figure 2.
Figure 2.
Regional association plot for rs112878080 (CHRNA3 locus at 15q25.1) using a combined European ancestry white dataset.
Figure 3.
Figure 3.
Regional association plot for rs116825096 (PDE11A locus at 2q31.2) using a COPDGene (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease study) African American dataset.
See this image and copyright information in PMC

References

    1. Hughes JMB, Pride NB. Examination of the carbon monoxide diffusing capacity (DLCO) in relation to its KCO and VA components. Am J Respir Crit Care Med. 2012;186:132–139. - PubMed
    1. Ranu H, Wilde M, Madden B. Pulmonary function tests. Ulster Med J. 2011;80:84–90. - PMC - PubMed
    1. Miniati M, Monti S, Pavlickova I, Bottai M. Survival in COPD: impact of lung dysfunction and comorbidities. Medicine (Baltimore) 2014;93:e76. - PMC - PubMed
    1. Sahin H, Naz I, Varol Y, Aksel N, Tuksavul F, Ozsoz A. COPD patients with severe diffusion defect in carbon monoxide diffusing capacity predict a better outcome for pulmonary rehabilitation. Rev Port Pneumol (2006) 2016;22:323–330. - PubMed
    1. Fishman A, Fessler H, Martinez F, McKenna RJ, Jr, Naunheim K, Piantadosi S, et al. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med. 2001;345:1075–1083. - PubMed

Publication types

MeSH terms

Associated data